Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Human Circovirus in Patients with Hepatitis, Hong Kong
Shusheng Wu
1, Cyril Chik-Yan Yip
1, Jianwen Situ
1, Zhiyu Li, Stanley Siu-Fung Ho, Jianpiao Cai, Jane Hau-Ching Poon, Nicholas Foo-Siong Chew, Jonathan Daniel Ip, Tom Wai-Hin Chung, Kelvin Hei-Yeung Chiu, Anna Jinxia Zhang, Estie Hon-Kiu Shun, James Yiu-Hung Tsoi, Jade Lee-Lee Teng, David Christopher Lung, Kelvin Kai-Wang To, Vincent Chi-Chung Cheng, Irene Oi-Lin Ng, Kwok-Yung Yuen, and Siddharth Sridhar
Author affiliation: The University of Hong Kong, Hong Kong, China (S. Wu, C.C.-Y. Yip, J. Situ, Z. Li, S.S.-F. Ho, J. Cai, J.H.-C. Poon, N.F.-S. Chew, J.D. Ip, A.J. Zhang, J.Y.-H. Tsoi, J.L.-L. Teng, K.K.-W. To, V.C.-C. Cheng, I.O.-L. Ng, K.-Y. Yuen, S. Sridhar); Queen Mary Hospital, Hong Kong (T.W.-H. Chung, K.H.-Y. Chiu, V.C.-C. Cheng); Queen Elizabeth Hospital, Hong Kong (D.C. Lung); Hong Kong Children's Hospital, Hong Kong (D.C. Lung); Centre for Virology, Vaccinology and Therapeutics, Hong Kong (E.H.-K. Shun, K.K.-W. To, K.Y. Yuen)
Main Article
Figure 5
Figure 5. IgM and IgG immunoblots of 7 patients for whom sufficient serum was available from study of HCirV in patients with hepatitis, Hong Kong. P indicates positive control, mouse polyclonal serum raised against HCirV cap protein. N indicates HCirV PCR-negative human donor sample. HCirV, human circovirus.
Main Article
Page created: October 04, 2024
Page updated: November 13, 2024
Page reviewed: November 13, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.